Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21652238 | 0.70 | ALDH1A1 (0.33) | ALDH1A1NPSR1 | |
| SCHEMBL19696511 | 0.68 | — | — | |
| SCHEMBL21672760 | 0.68 | TBXAS1 (0.31) | — | |
| SCHEMBL20847874 | 0.68 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL173202 | 0.67 | — | — | |
| SCHEMBL19700906 | 0.67 | PI4KA (0.35) | ALDH1A1NPSR1 | |
| SCHEMBL10183098 | 0.66 | HSP90AA1 (0.41) | ALDH1A1 | |
| SCHEMBL24936175 | 0.64 | HSP90AA1 (0.41) | ALDH1A1NPSR1 | |
| SCHEMBL8525654 | 0.62 | — | — | |
| SCHEMBL14037355 | 0.61 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2020-11-12 | — | — | US | disclosed |
| US-10626129-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190270759-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2019-09-05 | — | — | US | disclosed |
| US-20170342094-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2017-11-30 | — | — | US | disclosed |
| US-9777024-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150191469-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-07-09 | — | — | US | disclosed |
| US-9029391-B2 | Isoquinoline compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2015-04-30 | — | — | US | disclosed |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270759-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885NPSR1 2162/4885 |
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885NPSR1 2162/4885 |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885NPSR1 2162/4885 |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 751/4885NPSR1 2709/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885NPSR1 2162/4885 |
| US-20170342094-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885NPSR1 2162/4885 |
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | ALDH1A1 415/4885NPSR1 2875/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885NPSR1 2162/4885 |
| US-20150191469-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | CCR5, CD4, HAVCR2 | ALDH1A1 1971/4885NPSR1 3651/4885 |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | AZI2, TPMT, INMT | ALDH1A1 1779/4885NPSR1 3159/4885 |
| US-10626129-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885NPSR1 2162/4885 |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | MAVS, CCR5, NFATC1 | ALDH1A1 3054/4885NPSR1 4455/4885 |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | ALDH1A1 415/4885NPSR1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.